Now that Roche Holding AG has digested its Foundation Medicine and Flatiron acquisitions from a few years ago, it has looked to add more digital capabilities in a couple of recent deals. The earlier big-ticket tie-ups by the Basel, Switzerland-based pharma added genomic and real-world data analytics to deepen the knowledge driving Roche’s R&D efforts, particularly in oncology.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cue Health.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abound Bio, Advanced Molecular Services, Doctor On Demand, Foundation Medicine, Health Technology Solutions, Innovaqor, Integral Molecular, Lexent Bio, PRA, Quidel, Rennova Health, Tpt Global Tech.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: AACC, Akadeum, Calmare Therapeutics, Cota, Curadigm, Healgen, Helixbind, Hematogenix, Huma, Menarini Silicon Biosystems, Nanobiotix, Nanocellect, Neuspera, Orasure Technologies, Roche, Tyto Care, Vivera Pharmaceuticals.
Hong Kong – South Korea’s Lunit Inc. is currently in the process of applying for U.S. FDA approval for Lunit Insight Mmg, its AI software that analyzes mammography images to detect breast cancer. Other markets that the company targets entering include South America, the Middle East, and Asia Pacific, Jussarang Lee, communications manager at Lunit, told BioWorld. Founded in 2013, the Seoul-based company uses artificial intelligence to develop cancer diagnostics and therapeutics.
TORONTO – Seven years after setting up shop in downtown Toronto, high resolution, surgical imaging med-tech company Perimeter Medical Imaging Inc. (PMI) is still wrestling with a statistical heartbreaker: 1 in 4 patients told to return for a second surgery to remove cancerous breast tissue after the first surgery failed to get it all. Now PMI has said it can cut that number down dramatically thanks to a $7.44 million investment from the Austin, Texas-based Cancer Prevention and Research Institute of Texas (CPRIT) to identify wayward breast cancer cells using artificial intelligence technology.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Feedback, Gelesis, Philips, Zoll.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Airos Medical, GE Healthcare, Gynesonics, Quest Diagnostics.
RSS
